Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $28.25 and last traded at $28.5290, with a volume of 68587 shares changing hands. The stock had previously closed at $26.40.

Analyst Upgrades and Downgrades

TYRA has been the subject of a number of research analyst reports. Wedbush lifted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Oppenheimer reiterated an “outperform” rating and set a $36.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

Tyra Biosciences Price Performance

The firm’s 50-day moving average is $20.93 and its two-hundred day moving average is $15.06. The company has a market cap of $1.55 billion, a P/E ratio of -15.42 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Tyra Biosciences

In related news, Director Robert J. More sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TYRA. Federated Hermes Inc. grew its stake in Tyra Biosciences by 586.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter worth about $133,000. Russell Investments Group Ltd. raised its stake in shares of Tyra Biosciences by 27.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after buying an additional 1,668 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Tyra Biosciences in the second quarter worth about $177,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.